StocksMedium•25 September 2026•
1 min read
Novo Nordisk Enters €1.17B Licensing Deal with Nanexa for Drug Delivery Tech
Key Facts
1Novo Nordisk signed an exclusive license agreement with Swedish firm Nanexa to utilize its PharmaShell drug delivery technology.
2The total potential value of the deal is approximately €1.17 billion, including upfront payments and development milestones.
Novo Nordisk signed an exclusive license agreement with Swedish firm Nanexa to utilize its PharmaShell drug delivery technology. Investing.com reported that the total potential value of the deal is approximately €1.17 billion, encompassing upfront payments and various development milestones.
The partnership aims to enhance Novo Nordisk's drug delivery capabilities, specifically focusing on long-acting formulations within its metabolic disease pipeline. This R&D investment secures proprietary delivery technology intended to support the company's long-term clinical development goals.